Document Detail

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines.
MedLine Citation:
PMID:  15356213     Owner:  NLM     Status:  MEDLINE    
We have recently demonstrated the benefits of glucagon-like peptide-1 (GLP-1) in enhancing regional and global myocardial function after reperfusion in the clinical setting of acute myocardial infarction. We hypothesized that GLP-1 facilitates recovery from myocardial stunning after an ischemic event. To investigate this, we administered GLP-1 (1.5 pmol/kg/min) to six dogs undergoing 10-min occlusion of the left circumflex coronary artery, followed by 24-h reperfusion. We compared the responses of coronary blood flow and regional thickening of the posterior wall with a group of eight vehicle-treated dogs undergoing the same occlusion-reperfusion protocol. Although recovery of coronary blood flow was identical, regional wall motion recovery occurred significantly ((*)p < 0.05) earlier (92 +/- 4 versus 57 +/- 5%(*) at 15 min) and was complete in the GLP-1-treated dogs, whereas residual contractile dysfunction persisted in the control group (99 +/- 4 versus 78 +/- 3%(*) at 24 h). This phenomenon was independent of changes in systemic hemodynamics or global systolic function. However, isovolumic left ventricular relaxation improved significantly in GLP-1-treated dogs. GLP-1 caused an insulinotropic effect, but no hypoglycemia. We conclude that GLP-1 enhances recovery from ischemic myocardial stunning after successful reperfusion.
Lazaros A Nikolaidis; Aaron Doverspike; Teresa Hentosz; Lee Zourelias; You-Tang Shen; Dariush Elahi; Richard P Shannon
Related Documents :
25179883 - Influence of the left ventricular types on qt intervals in hypertensive patients.
624163 - Effects of dimethyl propranolol (um-272; sc-27761) on myocardial ischemic injury in the...
7054063 - The determination of ck, ldh and its isoenzymes in pericardial fluid and its applicatio...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2004-09-08
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  312     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2004-12-16     Completed Date:  2005-04-13     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  303-8     Citation Subset:  IM    
Cardiovascular Research Institute, Department of Medicine, Allegheny General Hospital, 320 East North Ave., Pittsburgh, PA 15212, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Circulation
Disease Models, Animal
Glucagon / therapeutic use*
Glucagon-Like Peptide 1
Myocardial Ischemia / complications
Myocardial Reperfusion Injury / prevention & control*
Myocardial Stunning / prevention & control*
Peptide Fragments / therapeutic use*
Protein Precursors / therapeutic use*
Grant Support
R01-A6 023125//PHS HHS
Reg. No./Substance:
0/Peptide Fragments; 0/Protein Precursors; 89750-14-1/Glucagon-Like Peptide 1; 9007-92-5/Glucagon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Extreme stretch growth of integrated axons.
Next Document:  Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma ago...